Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss-Reference-Cited by-同舟云学术

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

Published:2021-10-04 Issue:1 Volume:24 Page:94-105
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Wharton Sean¹^ORCID,Calanna Salvatore²,Davies Melanie³⁴^ORCID,Dicker Dror⁵,Goldman Bryan²,Lingvay Ildiko⁶^ORCID,Mosenzon Ofri⁷^ORCID,Rubino Domenica M.⁸,Thomsen Mette²,Wadden Thomas A.⁹,Pedersen Sue D.¹⁰

Affiliation:

1. York University, McMaster University and Wharton Weight Management Clinic Toronto Ontario Canada

2. Novo Nordisk A/S Søborg Denmark

3. Diabetes Research Centre University of Leicester Leicester UK

4. NIHR Leicester Biomedical Research Centre Leicester UK

5. Internal Medicine Department & Obesity Clinic, Hasharon Hospital‐Rabin Medical Center, Petach‐Tikva, Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

6. Departments of Internal Medicine/Endocrinology and Population and Data Sciences University of Texas Southwestern Medical Center Dallas Texas USA

7. Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center; Faculty of Medicine Hebrew University of Jerusalem Jerusalem Israel

8. Washington Center for Weight Management and Research Arlington Virginia USA

9. Department of Psychiatry, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

10. C‐ENDO Diabetes & Endocrinology Clinic Calgary Calgary Alberta Canada

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14551

Reference46 articles.

1. Progress and challenges in anti-obesity pharmacotherapy

2. The ABCD of Obesity: An EASO Position Statement on a Diagnostic Term with Clinical and Scientific Implications